NASDAQ:TYRA Tyra Biosciences Q2 2026 Earnings Results & Report $20.36 +0.39 (+1.95%) As of 02:27 PM Eastern This is a fair market value price provided by Massive. Learn more. Tyra Biosciences missed analyst earnings expectations in its Q2 2026 results, released August 4, 2026. The company reported EPS of -$0.69 versus the -$0.6499 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 4, 2026TimeAfter Market ClosesConference Call4:00 PM ET Tyra Biosciences EPS ResultsActual EPS-$0.69Consensus EPS -$0.6499Beat/MissMissed by -$0.0401One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersTyra Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsTyra Biosciences' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tyra Biosciences Q2 2026 Earnings FAQ Did Tyra Biosciences beat earnings estimates for Q2 2026? Tyra Biosciences (NASDAQ:TYRA) reported earnings of -$0.69 per share for Q2 2026, missing the consensus estimate of -$0.6499. The report was announced on Tuesday, August 4, 2026. When is Tyra Biosciences' next earnings date? Tyra Biosciences' next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Tyra Biosciences on the company's earnings history page. Tyra Biosciences Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAOctober 8 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAOctober 6 at 4:50 PM | globenewswire.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 9 at 1:00 AM | The Oxford Club (Ad)Raymond James Updates Healthcare Top Picks for OctoberOctober 3, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAOctober 1, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRASeptember 29, 2026 | globenewswire.comSee More Tyra Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tyra Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tyra Biosciences and other key companies, straight to your email. Email Address About Tyra BiosciencesTyra Biosciences (NASDAQ:TYRA) is a clinical-stage biotechnology company focused on developing precision medicines for cancers and other diseases driven by genetic alterations. The company uses its proprietary SNAP platform to design small-molecule therapies intended to selectively target clinically important mutations while addressing resistance mechanisms that can limit existing treatments. Tyra’s lead development program is TYRA-300, an orally administered, selective FGFR3 inhibitor being evaluated for the treatment of FGFR3-driven cancers, including urothelial carcinoma. The company is also investigating TYRA-300 in skeletal dysplasia, including achondroplasia, and is developing additional FGFR-targeted programs for oncology indications. Founded in 2018 and headquartered in Carlsbad, California, Tyra Biosciences conducts research and clinical development activities through its operations in the United States. The company was co-founded by Todd Harris, who serves as chief executive officer and is involved in guiding its drug-discovery and development strategy.View Tyra Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
